



ALMA MATER STUDIORUM  
UNIVERSITÀ DI BOLOGNA  
DIPARTIMENTO DI  
SCIENZE MEDICHE E CHIRURGICHE

POLICLINICO DI  
**SANT'ORSOLA**

 **SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA**  
Azienda Ospedaliero - Universitaria di Bologna

# New Drugs in Hematology

**President:** Pier Luigi Zinzani

**Co-President:** Michele Cavo

**Bologna,  
Royal Hotel Carlton  
January 15-17, 2024**

**BOLOGNA ROYAL HOTEL CARLTON**

**PROGRAM**

## Auspices

**ALMA MATER STUDIORUM  
UNIVERSITÀ DEGLI STUDI DI BOLOGNA**

**REGIONE EMILIA-ROMAGNA**

**AZIENDA OSPEDALIERO-UNIVERSITARIA  
DI BOLOGNA**

**AIL ASSOCIAZIONE ITALIANA CONTRO  
LE LEUCEMIE - LINFOMI E MIELOMA**

SEZIONE DI BOLOGNA

**SIE - SOCIETÀ ITALIANA DI EMATOLOGIA**

**SIES - SOCIETÀ ITALIANA DI EMATOLOGIA  
SPERIMENTALE**



## Faculty

<b>Haifa K. Othman</b>	<b>Al-Ali</b>	Halle, Germany	<b>Shaji Andrew</b>	<b>Kumar Kuykendall</b>	Rochester, USA
<b>Stephen M. Paul M. Massimiliano</b>	<b>Al-Sawaf</b>	Cologne, Germany	<b>Ann S. Marco</b>	<b>La Casce Ladetto</b>	Tampa, USA
<b>Massimo Jennifer</b>	<b>Ansell Barr</b>	Rochester, USA	<b>Mark Franco</b>	<b>Levis Locatelli</b>	Boston, USA
<b>Tim H. Elizabeth L. John C. Carmelo</b>	<b>Bonifacio Breccia</b>	Rochester, USA	<b>Maurizio Jean-Marie</b>	<b>Martelli Michot</b>	Alessandria, Italy
<b>Fausto Michele Chan</b>	<b>Brown Bruemmendorf</b>	Verona, Italy	<b>Paola Phillippe</b>	<b>Minetto Moreau</b>	Baltimore, USA
<b>Bruce D. Marilena Paolo Antonio Alexey V. Stéphan Michael Daan Johannes A. Kieron Jonathan Guillermo Heinz Paola Mehdi Steven M. Swaminathan P. Elias J. Ryan W. Caron A. Wojciech Won Seog</b>	<b>Budde Byrd Carlo-Stella Castagnetti Cavo Cheah Cheson Ciciarello Corradini Curti Danilov De Botton Dickinson Dierickx Duell Dunleavy Friedberg Garcia-Manero Gisslinger Guglielmelli Hamadani Horwitz Iyer Jabbour Jacobs Jacobson Jurczak Kim</b>	Rome, Italy	<b>Saatva S. Paola Francesca Cristina Alessandro Delphine Andreas Katy Marco David A. Stephen J. Tanya Michele Marion Anna Alessandra Catherine Suzanne Alessandro M. Adriano Nicola Andrew H. Jasmine Elena Pier Luigi</b>	<b>Neelapu Neri Palandri Papayannidis Rambaldi Rea Reiter Rezvani Ruella Sallman Schuster Siddiqi Spina Subklewe Sureda Tedeschi Thieblemont Trudel Vannucchi Venditti Vianelli Wei Zain Zamagni Zinzani</b>	Rome, Italy
		Boston, USA			Rome, Italy
		Aachen, Germany			Villejuif, France
		Duarte, USA			Genova, Italy
		Cincinnati, USA			Nantes, France
		Rozzano-MI, Italy			Phoenix, USA
		Bologna, Italy			Houston, USA
		Bologna, Italy			Calgary, Canada
		Perth, Australia			Bologna, Italy
		Washington, USA			Bologna, Italy
		Bologna, Italy			Bergamo, Italy
		Milan, Italy			Paris, France
		Bologna, Italy			Heidelberg, Germany
		Duarte, USA			Houston, USA
		Villejuif, France			Philadelphia, USA
		Melbourne, Australia			Tampa, USA
		Leuven, Belgium			Philadelphia, USA
		Wuerzburg, Germany			Duarte, USA
		Washington, USA			Aviano-PN, Italy
		Rochester, USA			Munich, Germany
		Houston, USA			Barcelona, Spain
		Wien, Austria			Milan, Italy
		Florence, Italy			Paris, France
		Milwaukee, USA			Toronto, Canada
		New York, USA			Florence, Italy
		Houston, USA			Rome, Italy
		Houston, USA			Bologna, Italy
		Charlotte, USA			Melbourne, Australia
		Boston, USA			Duarte, USA
		Krakow, Poland			Bologna, Italy
		Seoul, Korea			Bologna, Italy

## Monday, January 15, 2024

09.00 a.m. *Welcome and introduction*

### **SESSION I: CAR-T, update clinical trials and RWE**

*Chairman: P. Corradini*

09.15 a.m. HG-BCL - *S.J. Schuster*

09.45 a.m. Follicular lymphoma - *C.A. Jacobson*

10.15 a.m. Mantle cell lymphoma - *J. Munoz*

### **SESSION II: Hodgkin's lymphoma**

*Chairmen: S.M. Ansell, P.L. Zinzani*

10.45 a.m. Frontline advanced stage - *J. Friedberg*

11.00 a.m. 1<sup>st</sup> relapse - *S.M. Ansell*

11.15 a.m. New agents in R/R patients - *A.S. La Casce*

11.30 a.m. Treatment strategies in elderly patients - *A. Sureda*

11.45 a.m. Primary mediastinal lymphoma - *K. Dunleavy*

12.00 p.m. Grey zone lymphoma - *S.M. Ansell*

12.15 p.m. CAR-T - *F. Locatelli*

### **Lectures on PROTAC therapies**

*Chairman: B.D. Cheson*

12.50 p.m. NX-2127 - *A.V. Danilov*

01.10 p.m. BGB-16673 - *C. Cheah*

01.30 p.m. **Lunch**

### **SESSION III: Acute leukemias**

*Chairmen: A. Curti, A. Venditti*

02.30 p.m. Immunotherapy in AML: targeting immunosuppressive microenvironment - *M. Ciciarello*

02.45 p.m. Targeting CD123 in AML and BPDCN - *P. Minetto*

03.00 p.m. Anti-CD47 MoAbs in AML and MDS - *D.A. Sallman*

03.15 p.m. Immune checkpoint inhibitors in AML and MDS - *G. Garcia-Manero*

03.30 p.m. T-cell engagers in AML and ALL - *M. Subklewe*

03.45 p.m. IDH inhibitor: ivo, ena and beyond - *S. De Botton*

04.15 p.m. **Coffee break**

04.30 p.m. BCL2 inhibitors: not only venetoclax - *A.H. Wei*


04.45 p.m. Novel FLT3 inhibitors - *M. Levis*

05.00 p.m. Subcutaneous blinatumomab in adult ALL - *A. Rambaldi*

05.15 p.m. Menin-inhibitors - *C. Papayannidis*

05.30 p.m. Targeting the BCL2/BCLx pathway in T-ALL - *E.J. Jabbour*

05.45 p.m. CAR-T cells for adult ALL and AML - *M. Ruella*



**SESSION IV: Classical Ph1-neg myeloproliferative neoplasms**

*Chairmen: F. Palandri, A.M. Vannucchi*

- 08.30 a.m. Cytoreduction in low-risk PV: when, and which drug? - *H. Gisslinger*
- 08.45 a.m. Hydroxyurea, interferons, ruxolitinib or clinical trials: what sequence in polycythemia vera? - *F. Palandri*
- 09.00 a.m. The future of 1<sup>st</sup> line therapy in myelofibrosis - *A. Kuykendall*
- 09.15 a.m. Second-line therapy of myelofibrosis - *H.K. Al-Ali*
- 09.30 a.m. What is disease modification in myelofibrosis - *A. Reiter*
- 09.45 a.m. MPNs in accelerated/blast phase - *P. Guglielmelli*

**SESSION V: Non-Hodgkin's lymphoma (I)**


*Chairmen: C. Carlo-Stella, M. Ladetto*

- 10.00 a.m. Tafasitamab - *J.A. Duell*
- 10.15 a.m. Epcoritamab - *C. Thieblemont*
- 10.30 a.m. Glofitamab - *M. Dickinson*
- 10.45 a.m. Mosunetuzumab - *E.L. Budde*
- 11.00 a.m. Odronebamab - *W.S. Kim*
- 11.15 a.m. TNB-486 - *R.W. Jacobs*
- 11.30 a.m. Polatuzumab vedotin - *B.D. Cheson*
- 11.45 a.m. Loncastuximab tesirine - *M. Hamadani*
- 12.00 p.m. Tazemetostat - *J.M. Michot*
  
- 12.45 p.m. Lunch

**SESSION VI: Non-Hodgkin's lymphoma (II)**

*Chairmen: M. Martelli, M. Spina*

- 02.00 p.m. Zilovetamab - *P.M. Barr*
- 02.15 p.m. Linperlisib - *S.P. Iyer*
- 02.30 p.m. Pirtobrutinib - *W. Jurczak*
- 02.45 p.m. Zanubrutinib - *P.L. Zinzani*
- 03.00 p.m. Golidocitinib - *W.S. Kim*
- 03.15 p.m. Valemetostat - *S.M. Horwitz*
- 03.30 p.m. Iberdomide - *C. Thieblemont*
- 03.45 p.m. Golcadomide - *J.M. Michot*
- 04.00 p.m. CDK9 inhibitors - *J. Zain*



**SESSION VII: Non-Hodgkin's lymphoma  
- The next steps of CAR-T**

*Chairman: S.J. Schuster*

- 04.30 p.m. New generations of CAR-T - *S.J. Schuster*
- 04.45 p.m. Allo CAR-T - *S.S. Neelapu*
- 05.00 p.m. CAR-NK cells - *K. Rezvani*
- 05.15 p.m. Gamma delta CART19 - *S.S. Neelapu*

**SESSION VIII: Chronic myeloid leukemia**

*Chairmen: M. Breccia, F. Castagnetti*

- 05.45 p.m. Status of the art of treatment - *M. Breccia*
- 06.00 p.m. Asciminib - *D. Rea*
- 06.15 p.m. Ponatinib - *F. Castagnetti*
- 06.30 p.m. Second generation TKIs - *T.H. Bruemmendorf*
- 06.45 p.m. New agents - *M. Bonifacio*

**Lecture**

*Chairman: N. Vianelli*

- 08.45 a.m. Improving outcomes of EBV+ PTLID with T-cell immunotherapy - *D. Dierickx*

**SESSION IX: Chronic lymphocytic leukemia**

*Chairmen: W. Jurczak, A. Tedeschi*

- 09.30 a.m. Ibrutinib - *W. Jurczak*
- 09.45 a.m. Venetoclax - *O. Al-Sawaf*
- 10.00 a.m. Acalabrutinib - *J.C. Byrd*
- 10.15 a.m. Zanubrutinib - *J. Brown*
- 10.30 a.m. Pirtobrutinib - *W. Jurczak*
- 10.45 a.m. Nemtabrutinib - *J.C. Byrd*
- 11.00 a.m. BGB-11417 - *C. Cheah*
- 11.15 a.m. CAR-T - *T. Siddiqi*

**SESSION X: Multiple myeloma**

*Chairman: M. Cavo*

- 11.45 a.m. 2<sup>nd</sup> generation anti-BCMA and -GPRC5D autologous CAR-T - *E. Zamagni*
- 12.00 p.m. Antibody drug conjugates - *S. Trudel*
- 12.15 p.m. Bispecific antibodies - *P. Moreau*
- 12.30 p.m. Resistance mechanisms - *P. Neri*
- 12.45 p.m. T-cell directing therapies sequencing - *S. Kumar*
- 01.15 p.m. **Arrivederci**

## GENERAL INFORMATION

### MEETING VENUE

#### Royal Hotel Carlton

Via Montebello, 8 - 40121 Bologna, Italy

Phone +39 051 249361

[www.royalhotelcarltonbologna.com](http://www.royalhotelcarltonbologna.com)

### OFFICIAL LANGUAGE

English

### REGISTRATION

Registration is available at [www.ercongressi.it](http://www.ercongressi.it) - section "I nostri congressi/anno 2024"

The registration includes conference kit, participation in the scientific sessions, attendance certificate, coffee break, lunch, slides of the meeting.

### BADGE AND CERTIFICATE OF ATTENDANCE

All registered participants, speakers and sponsors will be given a badge which they must wear to be admitted to the scientific sessions. A certificate will be given to all participants at the end of the meeting.

### ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828-401090
- No. **6 CME** credits for Physicians (disciplines: Allergology and Clinical Immunology, Dermatology and Venereology, Hematology, Oncology, Pathological Anatomy, Clinical Biochemistry, Clinical Pathology), Biologists and Chemists
- Educational objective: "linee guida-protocolli-procedure"

### EUROPEAN CME CREDITS

The program of the "New Drugs in Hematology" has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 21 CME credits for Physicians, Biologists and Chemists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebah.org>.

### CHANGES

Parts of the program may be changed without notice.

## ACKNOWLEDGEMENTS

With the unrestricted educational grant of

abbvie

AstraZeneca

BeiGene

Bristol Myers Squibb™

Johnson&Johnson

Roche

Takeda

Daiichi-Sankyo

Lilly

GILEAD | Kite

GSK

MENARINI Stemline

nurix

Pierre Fabre

sobi  
rare strength

Vincerx  
PHARMA.

# New Drugs in Hematology

## **Scientific Secretariat**

**Pier Luigi Zinzani**

Istituto di Ematologia

“Lorenzo e Ariosto Seràgnoli”

Via Massarenti, 9 - 40138 Bologna, Italy

## **Organizing Secretariat**

**Studio E.R. Congressi**

Via De' Poeti, 1/7 - 40124 Bologna, Italy

Phone +39 051 4210559

E-mail: [ercongressi@ercongressi.it](mailto:ercongressi@ercongressi.it)

[www.ercongressi.it](http://www.ercongressi.it)